NeuBase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Current Liabilities (Tables)

9 Months Ended

Sep. 30, 2023


	As of September 30,		As of December 31,
	2023		2022
	Unaudited		Unaudited
Accrued compensation and benefits	$	87,359	$	171,572
Accrued consulting settlement		—		225,000
Accrued professional fees		120,845		241,808
Accrued research and development		—		20,684
Accrued franchise tax		29,680		217,440
Accrued restructuring		185,095		316,032
Other accrued expenses		39,207		35,120
Total	$	462,186	$	1,227,656